Ascentage is looking to use the IPO proceeds to advance its Phase III candidates for chronic or small lymphocytic leukemia ...

Gilead Sciences continues its divergence out of its original infectious disease beginnings and into cancer and now, more ...

Biotech giant Gilead Sciences, Inc. GILD has put up a strong performance amid a volatile market. Shares of this biotech giant ...

Galapagos NV. announced its plans to split into two listed entities by mid-2025 by spinning off its activities focused on ...

Gilead’s investment will let it assess the therapeutic potential of targeting STAT6, a transcription factor involved in IL-4 ...

South San Francisco biotech Pionyr was sold two years ago. Now three of its leaders want to test a trio of drugs beyond ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

After a run of court victories in a five-year patent dispute with the U.S. government, Gilead Sciences has agreed to settle with the Department of Justice (DOJ) and the Department of Health and ...

Kite Pharma is flying high with the addition of a new member to its senior leadership team. | Kite Pharma is flying high with ...

Shoreline Biosciences, a gene editing and cell therapy biotech, has let go of staffers dedicated to a cell therapy project ...

The biotech industry is booming thanks to the rising demand for personalized medicine, investment in innovations, and ongoing ...

Gilead Sciences and Danish dermatology specialist LEO Pharma announced a strategic partnership, marking another move outside ...